WO2004005492A2 - Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant - Google Patents

Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant Download PDF

Info

Publication number
WO2004005492A2
WO2004005492A2 PCT/RU2003/000039 RU0300039W WO2004005492A2 WO 2004005492 A2 WO2004005492 A2 WO 2004005492A2 RU 0300039 W RU0300039 W RU 0300039W WO 2004005492 A2 WO2004005492 A2 WO 2004005492A2
Authority
WO
WIPO (PCT)
Prior art keywords
mass
miκροφlορy
strain
κοε
ποleznοy
Prior art date
Application number
PCT/RU2003/000039
Other languages
English (en)
Russian (ru)
Other versions
WO2004005492A3 (fr
Inventor
Galina Gennadievna Alekhina
Alexander Nickolaevich Suvorov
Original Assignee
Galina Gennadievna Alekhina
Alexander Nickolaevich Suvorov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from RU2002118758A external-priority patent/RU2220199C1/ru
Priority claimed from RU2002118757/15A external-priority patent/RU2227039C2/ru
Application filed by Galina Gennadievna Alekhina, Alexander Nickolaevich Suvorov filed Critical Galina Gennadievna Alekhina
Priority to AU2003211648A priority Critical patent/AU2003211648A1/en
Publication of WO2004005492A2 publication Critical patent/WO2004005492A2/fr
Publication of WO2004005492A3 publication Critical patent/WO2004005492A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/46—Streptococcus ; Enterococcus; Lactococcus

Definitions

  • SIGNIFICANT FOX (DR. 26) 2 due to the antagonism, it suppresses growth and the reproduction of pathogenic bacteria (2)
  • This strain is also effective in the gastrointestinal tract and is able to dispose of small quantities of food in the small intestine. However, this strain does not suffice for a sufficiently fast antagonistic activity and stability of various antibacterials.
  • the vaginosis treatment is known to be effective (7) (Application no. 98122669/14; ⁇ 7 ⁇ 61 ⁇ 9/02; published September 27, 2000 (1); 1 ⁇ 9610359.3)
  • One or more local anesthetics are known to be effective (7) (Application no. 98122669/14; ⁇ 7 ⁇ 61 ⁇ 9/02; published September 27, 2000 (1); 1 ⁇ 9610359.3)
  • a well-known therapeutic and medicinal product contains basic, microbial mass of live bacteria (eubiotic) and biologically active, non-immune, non-inflammatory substances
  • ⁇ aches ⁇ ve bi ⁇ l ⁇ giches ⁇ i a ⁇ ivny ⁇ ing ⁇ edien ⁇ v in izves ⁇ n ⁇ m lechebn ⁇ - ⁇ ila ⁇ iches ⁇ m ⁇ e ⁇ a ⁇ a ⁇ e is ⁇ lz ⁇ vany vesches ⁇ va of g ⁇ u ⁇ y, v ⁇ lyuchayuschey gia ⁇ u ⁇ n ⁇ vuyu ⁇ isl ⁇ u, liz ⁇ tsim, in ⁇ e ⁇ e ⁇ ny, immun ⁇ gl ⁇ buliny, bi ⁇ l ⁇ giches ⁇ i a ⁇ ivnye ⁇ e ⁇ idy, an ⁇ imi ⁇ bnye, an ⁇ ivi ⁇ usnye or an ⁇ imi ⁇ iches ⁇ ie vesches ⁇ va and / or i ⁇ ⁇ azn ⁇ e s ⁇ che ⁇ anie.
  • SIGNIFICANT FOX (DR. 26) 4 TEMPERATURE), which leads to a low clinical effect.
  • SIGNIFICANT FOX (DR. 26) 5 Useful microorganisms use live, unlicensed, microbial mass of the allocated by the authors of the new Storm
  • 25 is ⁇ lz ⁇ van ⁇ a ⁇ mal and or ⁇ al ⁇ and / or ⁇ is ⁇ vaya mu ⁇ a, and / or other mel ⁇ dis ⁇ e ⁇ snaya ney ⁇ alnaya for ⁇ lezn ⁇ y mi ⁇ l ⁇ y and ⁇ zhi and slizis ⁇ y ⁇ chel ⁇ ve ⁇ a ⁇ sh ⁇ b ⁇ aznaya weight, and in ⁇ aches ⁇ ve zhi ⁇ v ⁇ g ⁇ ⁇ m ⁇ nen ⁇ a ⁇ sn ⁇ vy, ney ⁇ aln ⁇ g ⁇ for ⁇ lezn ⁇ y mi ⁇ l ⁇ y and ⁇ zhi and slizis ⁇ y ⁇ chel ⁇ ve ⁇ a, is ⁇ lz ⁇ van ⁇ oil and / or oil substitutes and / or oil mixture
  • ⁇ aya would ⁇ zv ⁇ lila with b ⁇ lsh ⁇ y d ⁇ ley d ⁇ s ⁇ vern ⁇ s ⁇ i, e ⁇ e ⁇ ivn ⁇ s ⁇ i and nadezhn ⁇ s ⁇ i v ⁇ ss ⁇ anavliva ⁇ mi ⁇ bi ⁇ tsen ⁇ z ⁇ ganizma chel ⁇ ve ⁇ a, m ⁇ gla would by ⁇ is ⁇ lz ⁇ vana for lechebn ⁇ - ⁇ ila ⁇ iches ⁇ i ⁇ s ⁇ eds ⁇ v and s ⁇ s ⁇ bna would ⁇ ed ⁇ v ⁇ ascha ⁇ and or lechi ⁇ disba ⁇ e ⁇ i ⁇ zy and in ⁇ e ⁇ tsi ⁇ nnye
  • SIGNIFICANT FOX (DR. 26) 7 and v ⁇ s ⁇ ali ⁇ elnye zab ⁇ levaniya ⁇ zhi and slizis ⁇ y ⁇ , ⁇ eshae ⁇ sya ⁇ a ⁇ zhe n ⁇ vym s ⁇ s ⁇ b ⁇ m ⁇ lucheniya ⁇ bi ⁇ iches ⁇ y ⁇ m ⁇ zitsii, za ⁇ lyuchayuschemsya in growing mi ⁇ bn ⁇ y ⁇ lezn ⁇ y mi ⁇ l ⁇ y mass, drying it and mixing with ⁇ m ⁇ nen ⁇ ami ⁇ sn ⁇ vy in ⁇ m in s ⁇ ve ⁇ s ⁇ vii with ⁇ edlagaemym
  • the 20 resulting output is up to 7.0, after which the received non-standard nutritional medium is sterilized by autoclaving at a pressure of 1 atm. for at least 20 minutes ⁇ Communication + 110-120 ° ⁇ .
  • SIGNIFICANT FOX (DR. 26) 8 vagina), on the processes of the exchange of substances in the body of the organism, in the stimulation of useful bacteria and cell-like protection of the products from the inoculation of
  • SIGNIFICANT FOX (DR. 26) 9
  • the growth rate is high in high salinity (6% NaCl), it is stable to ashamedy and to low ⁇ values (up to 3.0).
  • Such advantages of the new strain make it possible to successfully consume this strain with sugar or fat without a license, which is especially important for a reliable business.
  • the new strain can be introduced into the composition of medicinal preparations, possesses a significant and stable antimicrobial (bactericidal) effect, and is assisted by
  • SIGNIFICANT FOX 10 Landsfield. Bacteria vials have a spherical shape and are connected in chains. The size of the chain is from 2 to 10 bucks depending on the conditions of cultivation. ⁇ the liquid medium is the average size of the circuit - 6 units.
  • 10 solid agaric wraps are formed by angular, weakly convex, white shiny luminous areas of 1-3 mm in diameter.
  • the surface is very smooth, the surface is smooth, the structure is fine-grained, the structure is soft, oily. Just for fear - moderate, good.
  • the pigments that are diffused in the medium, the strain does not work.
  • Oxygen consumption Optional anaerobic.
  • General biochemistry catalysed, negative, cytoxidase-negative. Jobs not
  • SIGNIFICANT FOX (DR. 26) 11 clearly expressed medium, young people with methyl blue discolored weakly.
  • the optimum temperature is 37 + 2 ° ⁇ . It grows at 45 ° ⁇ . Weak temperature and 10 ° ⁇ . 5
  • the optimum value of ⁇ is 6.0. Saves a little more than 3 to 10 in the range of life. It grows in 4.0% of SAS, a moderate increase in 6.5% of SAS
  • the Storm ⁇ egosossss Gaestst L-3 grows at 37 + 2 ° ⁇ in the Boulevard or in the environment on the main soy protein (1.5%) "8 ⁇ from 2640"
  • SIGNIFICANT FOX (DR. 26) 12 adds 1 liter of water, delivers up to 7.0 and sterilizes autoclaving at a pressure of 1 atm. 20 minutes ⁇ and 110-120 ° ⁇ .
  • the particular strain of this product is its ability to conserve a high degree of life due to the use of food With this bacterium, they save 90% of their life at temperatures from -20 ° ⁇ to + 10 ° ⁇ for at least 6 months.
  • the strain contains the genes of enterocin ⁇ and enterocin ⁇ , corresponding to 10 bacteriocins of the second class. The presence of a gene is confirmed by an optimal reaction with the parameters of the enterocin gene - ⁇
  • Gaestst L-3 was introduced by a living laborer for one month.
  • SIGNIFICANT FOX 15
  • normal weight gain did not change
  • the body did not change
  • the color did not change and the color was shorter.
  • the depletion of lab-friendly livelihoods after the termination of the experiment also did not reveal any pathological changes in
  • Gaessht 15 b-3 (or mixture eg ⁇ s ⁇ sh ⁇ ammami ⁇ bi ⁇ i ⁇ v in ⁇ avny ⁇ ⁇ tsiya ⁇ ) be ⁇ u ⁇ in s ⁇ n ⁇ shenii with ⁇ sn ⁇ v ⁇ y, s ⁇ s ⁇ yaschey of sy ⁇ ucheg ⁇ su ⁇ g ⁇ ⁇ m ⁇ nen ⁇ a and zhi ⁇ v ⁇ g ⁇ ⁇ m ⁇ nen ⁇ a, ⁇ to ⁇ e ⁇ bes ⁇ echivae ⁇ in ⁇ nechn ⁇ m ⁇ du ⁇ e least ⁇ i ⁇
  • ⁇ a ⁇ sn ⁇ ve e ⁇ y ⁇ m ⁇ zitsii were ⁇ lucheny and a ⁇ bi ⁇ vany e ⁇ s ⁇ e ⁇ imen ⁇ aln ⁇ and ⁇ liniches ⁇ i ⁇ azlichnye va ⁇ ian ⁇ y lechebn ⁇ - ⁇ ila ⁇ iches ⁇ i ⁇ s ⁇ eds ⁇ v in ⁇ azlichn ⁇ y ⁇ me (suppositories; a ⁇ li ⁇ atsii; ⁇ as ⁇ il ⁇ i; ointments;. S ⁇ e ⁇ zhni and d ⁇ ) with shi ⁇ im s ⁇ e ⁇ m i ⁇ destination (v ⁇ s ⁇ ali ⁇ elnye
  • vaginal suppression Therapeutic and therapeutic drug in the form of vaginal suppression (vaginal suppository).
  • SIGNIFICANT FOX (DR. 26) 16 CASKAS or FAT CONDITIONER - 90.
  • vaginal suppression Therapeutic and therapeutic drug in the form of vaginal suppression (vaginal suppository). 5 Fertile biomass, as a rule, use a fresh plant
  • ⁇ i ⁇ bnuyu bi ⁇ massu in ⁇ aches ⁇ ve ⁇ y is ⁇ lzuyu ⁇ m ⁇ y ⁇ sad ⁇ (tsen ⁇ i ⁇ uga ⁇ ) ⁇ ul ⁇ u ⁇ sh ⁇ amm ⁇ v ⁇ eg ⁇ s ⁇ sssh Gaes ⁇ sh ⁇ 1, -3, 20 as ⁇ asShiz as ⁇ Y ⁇ sh ⁇ -91 (vzya ⁇ y ⁇ in ⁇ avny ⁇ ⁇ tsiya ⁇ ) with ⁇ bschim ⁇ i ⁇ m least October 10 ⁇ / g be ⁇ u ⁇ in ⁇ liches ⁇ ve on 18,0mg There is one application weighing 1 gram, and the main one is the rest, but at the same time the basis is in mass%: Natural flour - 5.6; Had ⁇ - 5.1;
  • Therapeutic and medicinal product in the form of a file for application to the mucous membrane of the oral cavity.
  • ⁇ i ⁇ bnuyu bi ⁇ massu in ⁇ aches ⁇ ve ⁇ y is ⁇ lzuyu ⁇ m ⁇ y ⁇ sad ⁇ 30 (tsen ⁇ i ⁇ uga ⁇ ) ⁇ ul ⁇ u ⁇ y sh ⁇ amma ⁇ eg ⁇ s ⁇ sssh Gaes ⁇ it 1, -3 with ⁇ i ⁇ m least October 10 ⁇ / g be ⁇ u ⁇ in ⁇ liches ⁇ ve 9,0mg and ⁇ sn ⁇ vu - ⁇ s ⁇ aln ⁇ e for ⁇ lucheniya ⁇ as ⁇ il ⁇ i ves ⁇ m 500 mg, ⁇ i. this is the basis in mass%: réelle ⁇ ⁇ gleich endeavour - 10.6;
  • a convenient biomass as a rule, uses a fresh plant
  • ⁇ / g is in the amount of 9.0 mg, and the main one is the rest for receiving the installation
  • the type of fat or the quality of the fat is 55.2.
  • Therapeutic and medicinal product in the form of a file for application to the mucous membrane of the prostate,
  • a convenient biomass as a rule, uses a fresh plant
  • the rate of fat or fat is 50.2.
  • a convenient biomass as a rule, uses a fresh plant
  • SIGNIFICANT FOX (DR. 26) 18 wet garden - 3;
  • Example 9 Therapeutic and medical treatment in the form of a treatment for the treatment of skin conditions (acute rash, nausea). 10 Microbial biomass, as a rule, uses a fresh seedlings
  • ⁇ / g is in the amount of 80.0 mg, and the main one is the rest for the production of a unit weighing 4000 mg., And this is the basis in weight%:
  • the average rate or fat rate is 92.3.
  • the additive adds dry components to the base and mixes up the bulk gain, it adds more
  • SIGNIFICANT FOX (DR. 26) 19 cooled to temperatures 28 - 37 ° ⁇ . Then mix thoroughly, mix, cool. Ready-made medical treatment facilities are available for the treatment of obsolete medical equipment.
  • the manufacturing process obtained in the process described in Example 9 is manufactured in a variety of ways.
  • the molten mass is subject to increased observance of conditions of abuse I place the camera in the freezer in the refrigerator
  • SIGNIFICANT FOX (DR. 26) 20 stylish packages.
  • mice of the main group were introduced vaginal benefits from the oil as well as with the Strain Gaestst-3.
  • the first control group introduced vaginal suppressions with antibiotic erotomycin;
  • the 20th vaginal group introduced vaginal benefits from oil
  • SIGNIFICANT FOX (DR. 26) 21 positive strains of the Gossesses Gesuit L-3, the connecting pipe was not processed, and the neutral infiltration was replaced by normal mucous disease.
  • Gaestst L-3 for the speed of cleansing the mucous membranes of the vagina from infection is comparable to
  • SIGNIFICANT FOX (DR. 26) 22 of the human body and the treatment and or treatment of dyspeptic infections and inflammatory and inflammatory diseases of the skin and mucous membranes.
  • the invention was obtained on the basis of a general pharmaceutical treatment, and a therapeutic treatment was obtained.
  • Gaesite 1, -3 Gaesite 1, -3.
  • the studied drug was prescribed for one vaginal suppression 1 time per day after the rehabilitation of the vagina for 7-10 days.
  • vaginal infections obtained on the basis of the proposed surgical treatment are effective in treating bacterial vaginosis and candidiasis.
  • SIGNIFICANT FOX (DR. 26) 23 industrial conditions in any region of the world on the basis of active pharmaceutical and digestive products, as well as small medical ones.
  • the products are manufactured in an environmentally friendly and low-cost environment.
  • antibiotics moreover, such as potent drugs like gentamycin, rhampamycin, oxacillin, cefuroxime, cepetaxim, cefalexin, methicillin); more pronounced antagonism to pathogenic bacteria; Higher viability in various aggressive media (such as, for example, acids and bile) and a high level of vitamins formation, which increase
  • 25 is ⁇ lzuem ⁇ g ⁇ in it ⁇ aches ⁇ ve mi ⁇ bn ⁇ y mass sh ⁇ amma ⁇ egos ⁇ sssh Gaesshn ⁇ L-3 d ⁇ ugimi ⁇ m ⁇ nen ⁇ ami ⁇ m ⁇ zitsii ⁇ zv ⁇ lyae ⁇ d ⁇ biva ⁇ sya ma ⁇ simaln ⁇ g ⁇ e ⁇ e ⁇ a - vys ⁇ y an ⁇ ag ⁇ nis ⁇ iches ⁇ y a ⁇ ivn ⁇ s ⁇ i in ⁇ n ⁇ shenii usl ⁇ vn ⁇ - ⁇ a ⁇ genn ⁇ y and ⁇ atogenn ⁇ y mi ⁇ l ⁇ y for lechebn ⁇ - ⁇ ila ⁇ iches ⁇ i ⁇ s ⁇ eds ⁇ v, ch ⁇ susches ⁇ venn ⁇ ⁇ asshi ⁇ yae ⁇ s ⁇ e ⁇ u is ⁇ lz ⁇ vaniya ⁇ m ⁇ zitsii: ⁇ na m ⁇ zhe ⁇ by ⁇
  • SIGNIFICANT FOX (DR. 26) 24 pharmaceuticals (pharmaceuticals, pharmaceuticals, capsules, even, supplies) and others. The commercial operation may be done both with and without fats.
  • SIGNIFICANT FOX (DR. 26) 25 b.
  • International application ⁇ réelle ⁇ ., ⁇ réelle ⁇ ., ⁇ Services ⁇ ⁇ . ⁇ agtasei ⁇ sa ⁇ s ⁇ t ⁇ zSh ⁇ z G ⁇ g ⁇ e ⁇ gea ⁇ te ⁇ ⁇ G sgo ⁇ s e ⁇ a ⁇ zez. ⁇ 9722351, ⁇ published
  • Patent ⁇ 26 ° 2146526 received 05.05.1999; ⁇ 7 ⁇ 61 ⁇ 9/02, published on 03.20.2000

Abstract

La composition probiotique à base d'une souche d'entérocoques se rapporte aux recettes de nouveaux moyens de traitement et de prévention utilisés dans la prévention et le traitement d'infections bactériennes et virales ainsi que de dysbactérioses des muqueuses et de la peau; elle peut s'utiliser en médecine, en pharmacologie et en cosmétologie. En outre, l'invention appartient également au domaine de la microbiologie et notamment aux souches de bactéries-entérocoques utilisées en biotechnologie médicale ou alimentaire, avec des propriétés d'adhérence élevées, des propriétés antagonistes élevées par rapport aux bactéries gram-négatives du groupe intestinal ainsi que par rapport aux bactéries gram-positives et aux champignons; elles manifestent en autre une stabilité vis-à-vis de l'action de facteurs extrêmes. L'invention peut être produit à l'échelle industrielle dans n'importe quel région du monde sur la base des industries pharmaceutiques ou alimentaires existantes ainsi que dans des laboratoires microbiologiques et biotechnologiques. La fabrication de cette composition ne présente pas de dangers pour l'environnement et ne produit que peu de déchets. Selon l'invention, on fabrique à partir de la souche d'entérocoques ainsi obtenue une composition probiotique manifestant une activité antagoniste élevée vis-à-vis d'une microflore pathogène ou conditionnellement pathogène, pour moyens de traitement et de prévention et pour produits alimentaires et médicaux. L'invention, dont la faisabilité est confirmée par des nombreux tests en clinique et en laboratoire, garantit une efficacité élevée dans le domaines de prévention et de traitement des divers processus inflammatoires de la peau et des muqueuses; elle a fait ses preuves en cosmétologie et en dermatologie sous la forme d'applications pour la peau, de masques cosmétiques, de poudre médicinale, de pommades appliquées de l'extérieur, en gastro-entérologie, sous la forme de dragées ou pastilles pour l'estomac, les intestins et les muqueuses de la bouche, etc. Le procédé de fabrication de la composition probiotique est universel, fiable et sûr du point de vue de l'environnement.
PCT/RU2003/000039 2002-07-03 2003-02-06 Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant WO2004005492A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003211648A AU2003211648A1 (en) 2002-07-03 2003-02-06 Probiotic compound on the basis of enterococcus faecium strain l-3 for medical-prophylactic means and method of production thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
RU2002118758A RU2220199C1 (ru) 2002-07-03 2002-07-03 Штамм энтерококков enterococcus faecium l-3 для изготовления лечебно-профилактических средств и продуктов питания лечебно-профилактического назначения
RU2002118758 2002-07-03
RU2002118757 2002-07-03
RU2002118757/15A RU2227039C2 (ru) 2002-07-03 2002-07-03 Пробиотическая композиция с высокой антагонистической активностью в отношении условно-патогенной и патогенной микрофлоры для лечебно-профилактических средств и способ ее получения

Publications (2)

Publication Number Publication Date
WO2004005492A2 true WO2004005492A2 (fr) 2004-01-15
WO2004005492A3 WO2004005492A3 (fr) 2004-11-04

Family

ID=30117573

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/RU2003/000039 WO2004005492A2 (fr) 2002-07-03 2003-02-06 Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant

Country Status (2)

Country Link
AU (1) AU2003211648A1 (fr)
WO (1) WO2004005492A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008094065A1 (fr) * 2007-02-02 2008-08-07 Alexei Nikolaevich Parfenov MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES
JP2009538614A (ja) * 2006-05-28 2009-11-12 シプラ メドプロ リサーチ アンド デヴェロップメント （プロプライエタリー） リミテッド プロバイオティクス菌株及びこれに由来する抗菌性ペプチド
CN112608858A (zh) * 2020-12-17 2021-04-06 上海交大昂立股份有限公司 一种具有祛斑作用的益生菌组合物及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1043194A (en) * 1962-04-13 1966-09-21 Alfred Bird & Sons Ltd Dehydrated fermented milk products
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
EP0953289A2 (fr) * 1998-04-08 1999-11-03 Protein Technologies International, Inc. Substitut de lait à haute teneur en protéines et graisses et son procédé de préparation
EP1082964A1 (fr) * 1998-06-05 2001-03-14 Wakamoto Pharmaceutical Co., Ltd. Compositions contenant des bacteries lactiques, medicaments et aliments
EP1133991A1 (fr) * 1998-11-26 2001-09-19 Meito Sangyo Kabushiki Kaisha Compositions bacteriostatiques contre les salmonelles

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2142504C1 (ru) * 1999-02-16 1999-12-10 Хомичева Светлана Яковлевна Способ получения биологически активной добавки в сухой форме, содержащей бактерии-эубиотики, и начинка для хлебных или кондитерских изделий на ее основе

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1043194A (en) * 1962-04-13 1966-09-21 Alfred Bird & Sons Ltd Dehydrated fermented milk products
EP0904784A1 (fr) * 1997-09-22 1999-03-31 N.V. Nutricia Préparation nutritionnelle probiotique
EP0953289A2 (fr) * 1998-04-08 1999-11-03 Protein Technologies International, Inc. Substitut de lait à haute teneur en protéines et graisses et son procédé de préparation
EP1082964A1 (fr) * 1998-06-05 2001-03-14 Wakamoto Pharmaceutical Co., Ltd. Compositions contenant des bacteries lactiques, medicaments et aliments
EP1133991A1 (fr) * 1998-11-26 2001-09-19 Meito Sangyo Kabushiki Kaisha Compositions bacteriostatiques contre les salmonelles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CASAUS PILAR ET AL: "Enterocin B, a new bacteriocin from Enterococcus faecium T136 which can act synergistically with enterocin A" MICROBIOLOGY (READING), vol. 143, no. 7, 1997, pages 2287-2294, XP002257062 ISSN: 1350-0872 *
DATABASE WPI Section Ch, Week 200045 Derwent Publications Ltd., London, GB; Class D11, AN 2000-504687 XP002282423 & RU 2 142 504 C (KHOMICHEVA S YA), 10 December 1999 (1999-12-10) cited in the application *
ENNAHAR SAID ET AL: "Biochemical and genetic evidence for production of enterocins A and B by Enterococcus faecium WHE 81" INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 70, no. 3, 8 November 2001 (2001-11-08), pages 291-301, XP002257063 ISSN: 0168-1605 *
TO B C S ET AL: "SURVIVAL OF BREVIBACTERIUM LINENS (ATCC 9174) AFTER SPRAY DRYING, FREEZE DRYING, OR FREEZING" JOURNAL OF FOOD SCIENCE, INSTITUTE OF FOOD TECHNOLOGISTS. CHICAGO, US, vol. 62, no. 1, 1997, pages 167-171, XP002038915 ISSN: 0022-1147 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009538614A (ja) * 2006-05-28 2009-11-12 シプラ メドプロ リサーチ アンド デヴェロップメント （プロプライエタリー） リミテッド プロバイオティクス菌株及びこれに由来する抗菌性ペプチド
WO2008094065A1 (fr) * 2007-02-02 2008-08-07 Alexei Nikolaevich Parfenov MÉTHODE ET AGENT À BASE DE SOUCHES D'Enterococcus faecium M (VKPM B-3490) ET D'Enterococcus faecium M-3185 (VKPM B-3491) SERVANT AU TRAITEMENT D'HÉPATITES VIRALES
CN112608858A (zh) * 2020-12-17 2021-04-06 上海交大昂立股份有限公司 一种具有祛斑作用的益生菌组合物及其应用

Also Published As

Publication number Publication date
AU2003211648A1 (en) 2004-01-23
AU2003211648A8 (en) 2004-01-23
WO2004005492A3 (fr) 2004-11-04

Similar Documents

Publication Publication Date Title
US4314995A (en) Pharmaceutical lactobacillus preparations
Oyetayo et al. Potential of probiotics as biotherapeutic agents targeting the innate immune system
JP4623896B2 (ja) ヒトおよび動物に使用される細菌株、加工された植物抽出物およびプロバイオティック組成物
CA2833937C (fr) Souches de lactobacilles, compositions comprenant ces souches et utilisation des souches pour prevenir ou traiter des maladies provoqueespar le streptocoque pyogene
JP4410992B2 (ja) 細菌株、処理された植物抽出物、それらを含有する組成物、その調製方法、ならびにその治療的応用および産業的応用
JP2008106066A (ja) サポニン及び生菌を含有する組成物
JPH0656680A (ja) 凍結乾燥された乳酸菌を含有する栄養学的及び／又は薬学的組成物、それらの調製及び使用
ES2734994T3 (es) Quitina o sus derivados para la prevención y/o el tratamiento de parasitosis
JP5592640B2 (ja) 乳酸菌発酵ローヤルゼリーを含有する抗ストレス剤、その製造方法、視床下部−下垂体−副腎皮質系の活動抑制剤、及び交感神経−副腎髄質系の活動抑制剤
WO1998013068A1 (fr) Medicament prophylactique 'trisan'
CN110893193A (zh) 乳双歧杆菌bl-99的新应用
JP2019526258A (ja) 脱毛症防止、発毛促進または性機能改善能を有するリューコノストック・ホルザプフェリイ菌株及びこれを含む組成物
JPH09508782A (ja) 生物学的に活性な発酵乳製品アシドラクト−ナリネおよび同製品の製造方法
TW202008998A (zh) 胚芽乳酸桿菌gkm3之活性物質、含其之組合物及其促進長壽之用途
JP2000256202A (ja) 新規な生体浄化活性型乳酸菌製剤
ES2321602T3 (es) Composicion para fomentar la proliferacion de lactobacillus casei subsp.casei.
JP5502449B2 (ja) 腸内フローラバランス改善剤及びその製造方法
IE913766A1 (en) Antimicrobial composition
JP2006111573A (ja) バチルス・サブチルス菌株の使用及びその使用に用いられる菌株を含む食品
WO2004005492A2 (fr) Composition probiotique a base d'une souche d'enterocoques pour moyens de traitement et de prevention et procede de fabrication correspondant
JPH02503800A (ja) 炎症過程及びアレルギー性疾患の予防及び治療のための細菌性製剤
RU2130316C1 (ru) Лечебно-профилактический биопрепарат "бактиспорин"
CN113509495A (zh) 鼠李糖乳杆菌在缓解肠道炎症中的应用
WO2021071375A1 (fr) Eau potable fonctionnelle
EP1894995A4 (fr) Préparation biologique irilis à base de bactéries du genre bacillus contenant bacillus subtilis et bacillus licheniformis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AM AT AU AZ BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU ID IL IN IS JP KE KG KP KR KZ LK LT LU LV MD MN MX NO NZ PL PT RO RU SE SG SK TJ TM TR UA US UZ VN ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP